Table 3.
Randomized controlled trials in female pattern hair loss
| Author, year | Age, years | Intervention group | Comparison | Duration, weeks | Results, mean difference hair density/cm2 (SD) between baseline and end of the study | Side effects |
|---|---|---|---|---|---|---|
| Lucky et al, 200434 | 37 (mean) | ●2% MS twice daily, N=108 | ●Placebo, N=51 | 48 | ●2% MS: 20.7 (17.6) | ●2% MS: headache 2%, pruritus 0.6% |
| ●5% MS twice daily, N=101 | ●5% MS: 26.0 (19.5) ●Placebo: 9.4 (14.6) |
●5% MS: pruritus 5%, headache 4%, hypertrichosis 3% | ||||
| Tsuboi et al, 200735 | Over 20 | ●1% MS twice daily, N=120 | ●Placebo, N=120 | 24 | ●1% MS: 8.15 ●Placebo: 2.03 |
NA |
| Blume-Pevtavi et al, 201136 | 49.9 (mean) | ●5% MF once daily, N=50 | ●2% MS twice daily, N=50 | 24 | ●5% MF: 31.9 (19.9) ●2% MS: 28.4 (19.9) |
●5% MF: facial hypertrichosis 33%, hair shedding 12.5%, pruritus 8.9%, dermatitis 3.6%, headache 3.6%, nausea and breathlessness 1.8%, palpitation and tachycardia 1.8%, papules and pustules 1.8%, maculopapular rash 1.8% ●2% MS: facial hypertrichosis 51%, hair shedding 17.5%, headache 7%, palpitation and tachycardia 3.5%, ear swelling 1.8%, papules and pustules 1.8%, dermatitis: 1.8% |
Abbreviations: MS, minoxidil solution; MF, minoxidil foam; NA, not applicable.